Nuvectis Pharma (NVCT) FY2025 10-K Risk Factors: 9 New, 8 Dropped

What the changes say

Nuvectis Pharma ceased clinical development of NXP800 following its Phase 1b study while maintaining focus on NXP900, bringing new risks regarding supply chain, staffing, and regulatory hurdles.

What changed since the prior 10-K

New

NewRisks Related to Our Finances and Capital Requirements
Tariffs and other trade measures could adversely affect our business, results of operations, financial position and cash flows
U.S. trade policies and tariffs could increase research and development costs by raising prices on chemical reagents and laboratory equipment.
NewRisks Related to Our Finances and Capital Requirements
As of December 31, 2025, we were not aware of any tariffs impacting our operations
Inadequate funding or shutdowns at the FDA and SEC could disrupt agency operations and delay product development or review timelines.
NewRisks Related to Government Regulation
candidates involved. Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional nonclinical studies or clinical trials
Regulatory authorities may reject clinical applications or require additional studies due to insufficient data or undesirable side effects from product candidates.
NewRisks Related to Government Regulation
and prospects. In such case, we may also not have the resources to conduct new clinical trials and we may determine that further clinical development of any such drug candidate is not justified and may discontinue any such programs
Regulatory approvals may come with restricted indications, price caps, or costly post-marketing clinical trial requirements that harm commercial prospects.
NewRisks Related to our Intellectual Property
intellectual property developed by others. Therefore, we may miss potential opportunities to establish our patent position
Stopping clinical development of NXP800 and relying on NXP900 and its SRC and YES1 kinase inhibitors exposes the company to patent protection risks.
NewRisks Related to our Intellectual Property
fields, there may be a risk that third parties may allege they have patent rights encompassing our current or future product candidates, technologies or methods
Third parties may assert patent infringement claims regarding our product candidates or technologies due to undisclosed or newly issued patents.
NewRisks Related to our Reliance on Third Parties
In 2025, following the completion of the NXP800 Phase 1b study, we decided to cease the clinical development of NXP800 as we assess possible next steps, if any, in the development of the compound. We are therefore currently not planning any future manufacturing campaigns for NXP800
We ceased clinical development of NXP800 following its Phase 1b study and have no future manufacturing campaigns planned for the compound.
NewRisks Related to Managing Growth and Employee Matters
operating as a public company, we expect to need additional managerial, operational, sales, marketing, financial and other personnel, as well as additional facilities to expand our operations
Failing to hire 13 full-time employees and expand facilities could prevent successful execution of our development and commercialization goals.
NewRisks Related to Managing Growth and Employee Matters
corruption of clinical trial data from future clinical trials may result in delays in our regulatory approval efforts and could significantly increase our costs to recover or reproduce the data
Security breaches or IT disruptions at third-party vendors could corrupt clinical trial data and significantly increase recovery and legal costs.

Dropped

DroppedRisks Related to the Development of our Product Candidates
from the ongoing Phase 1b study of NXP800 in platinum-resistant ARID1a-mutated ovarian carcinoma. Any results observed in this preliminary analysis may not be predictive of future results
DroppedRisks Related to the Development of our Product Candidates
Our studies may fail to adequately demonstrate the safety, potency, purity, efficacy or any other necessary pharmacological properties of any of our current or future product candidates, which would prevent or delay development, regulatory approval and commercialization
DroppedRisks Related to Government Regulation
before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval
DroppedRisks Related to Government Regulation
current or future product candidates. This could delay commercialization of our products
DroppedRisks Related to our Intellectual Property
If we are unable to secure additional patent protection or maintain existing or future patent protection with respect to NXP800, NXP900, or any other proprietary products and technology we develop, our business, financial condition, results of operations, and prospects would be materially harmed
Setbacks from the ongoing Phase 1b study of NXP800 in ovarian carcinoma.
DroppedRisks Related to our Intellectual Property
We have licensed a patent family directed to additional compounds that modulate HSF1. A patent from this family has been granted in the U.S., and has a statutory expiration of April 2036, without considering any patent extensions that may or may not be possible
DroppedRisks Related to our Intellectual Property
agreement and might therefore terminate the license agreement, thereby removing or limiting our ability to develop and commercialize NXP800 or NXP900 (and other compounds covered by the licenses)
DroppedRisks Related to Managing Growth and Employee Matters
companies, including requiring establishment and maintenance of effective disclosure and financial controls and changes in corporate governance practices

Reworded

84% rewrittenRisks Related to Government Regulation
Obtaining and maintaining regulatory approval of our current or future product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our current or future product candidates in other jurisdictions
Clarified that foreign regulatory authorities must approve manufacturing, marketing, and promotion in respective countries rather than similar countries.
83% rewrittenRisks Related to Government Regulation
Denial of or delay in our receipt of required regulatory approvals may prevent or delay commercialization of our current or future product candidates and our ability to generate revenue may be materially impaired
Adjusted formatting and punctuation regarding NDA approvals by the FDA without altering the core regulatory delay risks.
76% rewrittenRisks Related to Government Regulation
In the United States, there have been a number of legislative and regulatory changes to the healthcare system that could affect our future results of operations and the future results of operations of our potential customers
Retained the exact text on legislative and regulatory healthcare changes while updating the risk heading.
75% rewrittenRisks Related to Managing Growth and Employee Matters
We will incur significant increased costs as a result of operating as a public company, and our management will be required to devote substantial time to compliance activities and initiatives
Expanded the public company reporting disclosure to explicitly include maintaining effective financial controls and corporate governance practices.
66% rewrittenRisks Related to our Intellectual Property
Third-party claims of intellectual property infringement, misappropriation or other violations may be costly and time consuming and may prevent or delay our product discovery and development efforts
Added a concluding clause addressing the large volume of issued patents and patent applications in our precision medicine landscape.
62% rewrittenRisks Related to Managing Growth and Employee Matters
We will need to grow the size of our organization, and we may experience difficulties in managing this growth
Updated the employee headcount reference date from February 21, 2025, to February 6, 2026, while maintaining the 13 full-time employee figure.
60% rewrittenRisks Related to the Development of our Product Candidates
Our development approach may never lead to marketable products
Retained the exact text regarding limitations of patient populations with specific molecular alterations.
47% rewrittenRisks Related to the Development of our Product Candidates
Difficulty in enrolling patients could delay or prevent clinical trials of our current or future product candidates
Retained the exact text regarding patient enrollment difficulties for rare and specific target diseases.
44% rewrittenRisks Related to the Development of our Product Candidates
We may not be able to submit IND applications to commence additional clinical trials based on the timelines that we expect, and even if we are able to do so, the FDA may not permit us to proceed
Was: We may not be able to submit IND applications to commence additional clinical trials on the timelines we expect, and even if we are able to, the FDA may not permit us to proceed
43% rewrittenRisks Related to Managing Growth and Employee Matters
Our business and operations would suffer in the event of computer system failures, cyber-attacks, or deficiencies in our or third parties’ cybersecurity
29% rewrittenRisks Related to our Intellectual Property
We have licensed one patent family covering the composition of matter for NXP900, which has been granted in the U.S., EU, Japan, China and is pending in the United Kingdom and Canada. The statutory expiration for patents in this patent family is April 2036, without considering any possible patent term extension
28% rewrittenRisks Related to our Reliance on Third Parties
We plan to rely on third parties to conduct our preclinical studies and clinical trials. If these third parties do not properly and successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval of or commercialize our current or future product candidates
27% rewrittenRisks Related to Ownership of our Common Stock
Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant influence over matters subject to stockholder approval
27% rewrittenRisks Related to Our Finances and Capital Requirements
Our limited operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability
25% rewrittenRisks Related to Ownership of our Common Stock
If equity research analysts do not publish research or reports about our business or if they publish negative evaluations of or downgrade our Common Stock, the price of our Common Stock could decline
21% rewrittenRisks Related to Government Regulation
Adverse pricing limitations may hinder our ability to recoup our investment in one or more of our current or future product candidates, even if any such current or future product candidate we may develop obtains marketing approval

All 53 risk factors

Headings as the filing states them, in filing order.

Risks Related to Our Finances and Capital Requirements

01Our limited operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability27% rewritten
02We have incurred losses since inception and anticipate that we will continue to incur losses for the foreseeable future. We may never achieve or maintain profitability
03Tariffs and other trade measures could adversely affect our business, results of operations, financial position and cash flowsNew
04As of December 31, 2025, we were not aware of any tariffs impacting our operationsNew
05Major public health issues, and specifically the policies and procedures implemented during the COVID-19 pandemic which are still in place, could have an adverse effect on our clinical trials, financial condition, results of operations, and other aspects of our business

Risks Related to the Development of our Product Candidates

06Our development approach may never lead to marketable products60% rewritten
07Clinical drug development involves a lengthy and expensive process with uncertain outcomes, clinical trials are difficult to design and implement, and any of our clinical trials could produce unsuccessful results or fail at any stage in the process
08Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of marketing approval for our current or future product candidates
09Difficulty in enrolling patients could delay or prevent clinical trials of our current or future product candidates47% rewritten
10The FDA’s acceptance of data generated for patients recruited outside the United States from clinical trials conducted in whole or in part outside the United States may be subject to certain conditions, if accepted at all
11We may not be able to submit IND applications to commence additional clinical trials based on the timelines that we expect, and even if we are able to do so, the FDA may not permit us to proceed44% rewritten
12We currently have no marketing and sales organization and have limited experience in marketing products. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell any approved product candidates, we may not be able to generate product revenue
13We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do

Risks Related to Government Regulation

14Denial of or delay in our receipt of required regulatory approvals may prevent or delay commercialization of our current or future product candidates and our ability to generate revenue may be materially impaired83% rewritten
15candidates involved. Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional nonclinical studies or clinical trialsNew
16and prospects. In such case, we may also not have the resources to conduct new clinical trials and we may determine that further clinical development of any such drug candidate is not justified and may discontinue any such programsNew
17Obtaining and maintaining regulatory approval of our current or future product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our current or future product candidates in other jurisdictions84% rewritten
18Non-compliance with European Union requirements regarding safety monitoring or pharmacovigilance can also result in significant financial penalties. Similarly, failure to comply with the European Union’s requirements regarding the protection of personal information can also lead to significant penalties and sanctions
19A variety of risks associated with marketing our current or future product candidates internationally could materially adversely affect our business
20Adverse pricing limitations may hinder our ability to recoup our investment in one or more of our current or future product candidates, even if any such current or future product candidate we may develop obtains marketing approval21% rewritten
21In the United States, there have been a number of legislative and regulatory changes to the healthcare system that could affect our future results of operations and the future results of operations of our potential customers76% rewritten
22If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business

Risks Related to our Intellectual Property

23intellectual property developed by others. Therefore, we may miss potential opportunities to establish our patent positionNew
24We have licensed one patent family covering the composition of matter for NXP900, which has been granted in the U.S., EU, Japan, China and is pending in the United Kingdom and Canada. The statutory expiration for patents in this patent family is April 2036, without considering any possible patent term extension29% rewritten
25If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed
26Third-party claims of intellectual property infringement, misappropriation or other violations may be costly and time consuming and may prevent or delay our product discovery and development efforts66% rewritten
27fields, there may be a risk that third parties may allege they have patent rights encompassing our current or future product candidates, technologies or methodsNew
28Changes to patent law in the United States and in foreign jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products
29We may be subject to claims challenging the inventorship or ownership of our intellectual property, including any patents we may own or in-license currently or in the future
30We may be subject to claims that we or our employees, consultants or independent contractors have wrongfully used or disclosed confidential information or alleged trade secrets of third parties or competitors or breached non-competition or non-solicitation agreements with our competitors
31If we do not obtain patent term extension and data exclusivity for any of our current or future product candidates we may develop, our business may be materially harmed
32If our trademarks and trade names are not adequately protected, we may not be able to build name recognition in our marks of interest and our business may be adversely affected

Risks Related to our Reliance on Third Parties

33We plan to rely on third parties to conduct our preclinical studies and clinical trials. If these third parties do not properly and successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval of or commercialize our current or future product candidates28% rewritten
34In 2025, following the completion of the NXP800 Phase 1b study, we decided to cease the clinical development of NXP800 as we assess possible next steps, if any, in the development of the compound. We are therefore currently not planning any future manufacturing campaigns for NXP800New
35Each of these risks could delay or prevent the completion of our preclinical or clinical trials or the approval of any of our current or future product candidates by the FDA or another foreign regulatory authority, result in higher costs or adversely impact commercialization of our current or future product candidates
36If our third-party manufacturers use hazardous and biological materials in a manner that causes injury or violates applicable law, we may be liable for damages

Risks Related to Managing Growth and Employee Matters

37We are highly dependent on our key personnel and anticipate hiring new key personnel. If we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy
38We will need to grow the size of our organization, and we may experience difficulties in managing this growth62% rewritten
39operating as a public company, we expect to need additional managerial, operational, sales, marketing, financial and other personnel, as well as additional facilities to expand our operationsNew
40We will incur significant increased costs as a result of operating as a public company, and our management will be required to devote substantial time to compliance activities and initiatives75% rewritten
41Our business and operations would suffer in the event of computer system failures, cyber-attacks, or deficiencies in our or third parties’ cybersecurity43% rewritten
42corruption of clinical trial data from future clinical trials may result in delays in our regulatory approval efforts and could significantly increase our costs to recover or reproduce the dataNew

Risks Related to Commercial Activities

43If any of our current or future product candidates do not achieve broad market acceptance among physicians, patients, healthcare payors and the medical community, the revenues from any such current or future product candidate may be limited
44If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our current or future product candidates

Risks Related to Ownership of our Common Stock

45We do not know whether an active, liquid and orderly trading market will develop for our Common Stock or what the market price of our Common Stock will be and, as a result, it may be difficult for you to sell your shares of our Common Stock
46Our growth is subject to economic and political conditions
47We do not intend to pay dividends on our Common Stock in the foreseeable future, so any returns will be limited to the value of our stock, which may be volatile
48If equity research analysts do not publish research or reports about our business or if they publish negative evaluations of or downgrade our Common Stock, the price of our Common Stock could decline25% rewritten
49Raising additional capital may cause dilution to our existing stockholders, restrict our operations, or require us to relinquish rights to our current or future technologies or product candidates
50Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant influence over matters subject to stockholder approval27% rewritten
51Our failure to meet the continuing listing requirements of the NASDAQ Capital Market could result in a de-listing of our securities
52We are an emerging growth company and a smaller reporting company, and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies and smaller reporting companies will make our common stock less attractive to investors
53Provisions of our certificate of incorporation, our bylaws and Delaware law may deter unsolicited takeovers and/or delay or prevent a change in control of our Company, including transactions in which our stockholders might otherwise receive a premium for their shares

Other Nuvectis Pharma 10-Ks

FY2024 10-K risk factors
52 risks
Nuvectis Pharma faces substantial clinical development and regulatory risks for its primary oncology product candidates NXP800 and NXP900. The company depends heavily on licensed intellectual property, third-party contractors, and key personnel to execute clinical trials. Operating as a public company with ongoing financial losses increases compliance costs and capital requirements.
Filed Feb 25, 2025

About this page

The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.